Perioperative Intravenous Dexamethasone to Enhance Early Recovery in Hip Arthroplasty for Fragility Hip Fracture: A Prospective Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251218005

Enrollment

Registered

2025-12-18

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with fragility-related femoral neck fractures. Dexamethasone Femoral neck fracture Post-operative functional recovery Bipolar hemiarthroplasty Total hip arthroplasty

Interventions

Perioperative IV dexamethasone 8 mg ,Perioperative NSS 2 ml

Experimental Drug,Placebo Comparator Other

group A,group B

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with fragility-related femoral neck fractures. 2.Age 60 years or older. 3.Fracture occurrence within 30 days. 4.Eligible for spinal anesthesia for intraoperative analgesia. 5.Classified as ASA physical status I to III. 6.Body weight between 40 and 80 kilograms. 7.Willing to participate and able to provide written informed consent. 8.Able to communicate, read, and write in the Thai language.

Exclusion criteria

Exclusion criteria: 1.Inability to ambulate or pre-existing locomotor disorders prior to the fracture. 2.Presence of multiple fractures. 3.Use of corticosteroids within the past 3 months. 4.Use of immunosuppressive medications within the past 3 months. 5.Use of strong opioids within the past 7 days. 6.Diagnosed with diabetes mellitus. 7.Suspected or confirmed active infection of any kind. 8.History of allergy to dexamethasone, opioids, paracetamol, omeprazole, lorazepam, tranexamic acid, or naproxen. 9.History of gastric ulcer, severe heart disease, liver failure, or renal failure. 10.Participants who decline to participate or request withdrawal from the study.

Design outcomes

Primary

Measure	Time frame
Cumulated Ambulation Score at 3 days after end of the intervention score	—

Secondary

Measure	Time frame
two minute walk test post op 3 day 2 week 6 week 12 week distance/meter,Timed get-up-and-go test post op 3 day 2 week 6 week 12 week time/second,Barthel Index post op 3 day 2 week 6 week 12 week point,EQ-VAS post op 3 day 2 week 6 week 12 week point,Visual Analogue Scale 12, 18, 24, 48 72 hr Visual analog scale 0-100,Morphine 12, 18, 24, 48 72 hr mg,Erythrocyte Sedimentation Rate,C-Reactive Protein, D-dimer before sx post sx 24 hr g/dl	—

Measure

Time frame

two minute walk test post op 3 day 2 week 6 week 12 week distance/meter,Timed get-up-and-go test post op 3 day 2 week 6 week 12 week time/second,Barthel Index post op 3 day 2 week 6 week 12 week point,EQ-VAS post op 3 day 2 week 6 week 12 week point,Visual Analogue Scale 12, 18, 24, 48 72 hr Visual analog scale 0-100,Morphine 12, 18, 24, 48 72 hr mg,Erythrocyte Sedimentation Rate,C-Reactive Protein, D-dimer before sx post sx 24 hr g/dl

—

Countries

Thailand

Contacts

Public ContactPongsom Luanghirun

BUDDHACHINARAJ PHITSANULOK HOSPITAL

knim2@hotmail.com0971166353

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026